AR051738A1 - Derivados de piridazin-3(2h)-ona, composicin farmaceutica, y uso del compuesto para fabricar medicamentos - Google Patents
Derivados de piridazin-3(2h)-ona, composicin farmaceutica, y uso del compuesto para fabricar medicamentosInfo
- Publication number
- AR051738A1 AR051738A1 ARP050102533A ARP050102533A AR051738A1 AR 051738 A1 AR051738 A1 AR 051738A1 AR P050102533 A ARP050102533 A AR P050102533A AR P050102533 A ARP050102533 A AR P050102533A AR 051738 A1 AR051738 A1 AR 051738A1
- Authority
- AR
- Argentina
- Prior art keywords
- mono
- groups
- hydroxycarbonyl
- alkoxycarbonyl
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Un compuesto de formula (1) en la que R1 representa: un átomo de H, un grupo alquilo, alquenilo o alquinilo que está opcionalmente sustituido con uno o más sustituyentes seleccionados de átomos de halogeno y grupos hidroxi, alcoxi, ariloxi, alquiltio, ariltio, oxo, amino, mono- o dialquilamino, acilamino, hidroxicarbonilo, alcoxicarbonilo, carbamoílo, o mono- o dialquilcarbamoílo; R2 representa un grupo heteroarilo monocíclico o policíclico que está opcionalmente sustituido con uno o más sustituyentes seleccionados de: átomos de halogeno; grupos alquilo y alquileno, que están opcionalmente sustituidos con uno o más sustituyentes seleccionados de átomos de halogeno y grupos fenilo, hidroxi,. alcoxi, ariloxi, alquiltio, ariltio, oxo, amino, mono- o dialquilamino, acilamino, hidroxicarbonilo, alcoxicarbonilo, carbamoílo o mono- o dialquilcarbamoílo, grupos fenilo, hidroxi, hidroxicarbonilo, hidroxialquilo, alcoxicarbonilo, alcoxi, cicloalcoxi, nitro, ciano, ariloxi, alquiltio, ariltio, alquilsulfinilo, alquilsulfonilo, alquilsulfamoilo, acilo, amino, mono- o dialquilamino, acilamino, hidroxicarbonilo, alcoxicarbonilo, carbamoílo, mono- o dialquilcarbamoílo, ureído, N-alquilureído, N',N-dialquilureído, alquilsulfamido, aminosulfonilo, mono- o dialquilaminosulfonilo, ciano, difluorometoxi o trifluorometoxi; R3 representa un grupo de formula G-L1-(CRR')n- en la que n es un numero enteo de 0 a 6; R y R' se seleccionan independientemente del grupo constituido por átomos de H y grupos alquilo inferior; L1 es un grupo de union seleccionado del grupo constituido por un enlace directo, grupos -CO-, -NRö-CO-, -O(CO)NRö, -NRö(CO)O-, -O(CO)-, -O(CO)O-, -(CO)O- y -O(RöO)(PO)O- en los que Rö se selecciona del grupo constituido por átomos de H y grupos alquilo inferior; G se selecciona de átomos de H y grupos alquilo, alquenilo, alquinilo, cicloalquilo, cicloalquenilo, heterociclilo, arilo, arilalquilo y heteroarilo, estando opcionalmente sustituidos dichos grupos con uno o más sustituyentes seleccionados de: átomos de halogeno; grupos alquilo y alquenilo, que están opcionalmente sustituidos con uno o más sustituyentes seleccionados de átomos de halogeno; y grupos hidroxi, alquilendioxi, alcoxi, cicloalcoxi, alquiltio, alquilsulfinilo, alquilsulfonilo, alquilsulfamoilo, amino, mono- o dialquilamino, acilamino, nitro, ,acilo, hidroxicarbonilo, alcoxicarbonilo, carbamoílo, mono- o dialquilcarbamoílo, ureído, N'- alquilureído, N',N-dialquilureído, alquilsulfamido, aminosulfonilo, mono- o dialquilaminosulfonilo, ciano, difluorometoxi o trifluorometoxi; con la condicion de que R3 no sea un átomo de H; R4 representa un grupo arilo o heteroarilo monocíclico o policíclico que está opcionalmente sustituido con uno o más sustituyentes seleccionados de: átomos de halogeno, grupos alquilo y alquenilo que están opcionalmente sustituidos con uno o más sustituyentes seleccionados de átomos de halogeno y grupos fenilo, hidroxi, hidroxialquilo, alcoxi, alquiltio, ariltio, oxo, amino, mono- o dialquilamino, acilamino, hidroxicarbonilo, alcoxicarbonilo, carbamoílo, mono- o dialquilcarbamoílo; y grupos hiroxi, alquilendioxi, alcoxi, cicloalcoxi, alquiltio, alquilsulfinilo, alquilsulfonilo, alquilsulfamoilo, amino, mono- o dialquilamino, acilamino, nitro, acilo, hidroxicarbonilo, alcoxicarbonilo, carbamoílo, mono- o dialquilcarbamoílo, ureído, N-alquilureído, N',N-dialquilureído, alquilsulfamido, aminosulfonilo, mono- o dialquilaminosulfonilo, ciano, difluorometoxi o trifluorometoxi; y las sales o N-oxidos farmacéuticamente aceptables de los mismos. Estos compuestos son utiles para tratar enfermedades como asma, enfermedad pulmonar obstructiva cronica, artritis reumatoide, dermatitis atopica, psoriasis o enfermedad del intestino irritable.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200401512A ES2251867B1 (es) | 2004-06-21 | 2004-06-21 | Nuevos derivados de piridazin-3(2h)-ona. |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051738A1 true AR051738A1 (es) | 2007-02-07 |
Family
ID=34956037
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050102533A AR051738A1 (es) | 2004-06-21 | 2005-06-21 | Derivados de piridazin-3(2h)-ona, composicin farmaceutica, y uso del compuesto para fabricar medicamentos |
Country Status (22)
Country | Link |
---|---|
US (1) | US20090029996A1 (es) |
EP (1) | EP1781621A1 (es) |
JP (1) | JP2008503531A (es) |
KR (1) | KR20070036137A (es) |
CN (1) | CN1976904A (es) |
AR (1) | AR051738A1 (es) |
AU (1) | AU2005254704A1 (es) |
BR (1) | BRPI0511344A (es) |
CA (1) | CA2570196A1 (es) |
EC (1) | ECSP067057A (es) |
ES (1) | ES2251867B1 (es) |
IL (1) | IL179741A0 (es) |
MX (1) | MXPA06014562A (es) |
NO (1) | NO20070319L (es) |
NZ (1) | NZ551284A (es) |
PE (1) | PE20060531A1 (es) |
RU (1) | RU2386620C2 (es) |
SG (1) | SG155943A1 (es) |
TW (1) | TW200610757A (es) |
UA (1) | UA87691C2 (es) |
WO (1) | WO2005123693A1 (es) |
ZA (1) | ZA200609399B (es) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
JO2769B1 (en) | 2005-10-26 | 2014-03-15 | جانسين فارماسوتيكا ان. في | Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor |
JO2849B1 (en) | 2007-02-13 | 2015-03-15 | جانسين فارماسوتيكا ان. في | Dopamine 2 receptor antagonists are rapidly hydrolyzed |
ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
ES2320954B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorio Almirall S.A. | Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona. |
US9086277B2 (en) * | 2007-03-13 | 2015-07-21 | Certusview Technologies, Llc | Electronically controlled marking apparatus and methods |
ES2400710T3 (es) | 2007-04-23 | 2013-04-11 | Janssen Pharmaceutica, N.V. | Tia(dia)zoles como antagonistas del receptor de dopamina 2 de disociación rápida |
EP2148873B1 (en) | 2007-04-23 | 2012-08-29 | Janssen Pharmaceutica, N.V. | 4-alkoxypyridazine derivatives as fast dissociating dopamine 2 receptor antagonists |
EP2096105A1 (en) | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
KR101609218B1 (ko) | 2008-07-31 | 2016-04-05 | 얀센 파마슈티카 엔.브이. | 속해리성 도파민 2 수용체 길항제로서의 피페라진-1-일-트리플루오로메틸-치환된-피리딘 |
UY32297A (es) | 2008-12-22 | 2010-05-31 | Almirall Sa | Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico |
EP2221055A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function |
EP2221297A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases |
EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
EP2338888A1 (en) | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
EP2360158A1 (en) | 2010-02-18 | 2011-08-24 | Almirall, S.A. | Pyrazole derivatives as jak inhibitors |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
EP2394998A1 (en) * | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
EP2397482A1 (en) | 2010-06-15 | 2011-12-21 | Almirall, S.A. | Heteroaryl imidazolone derivatives as jak inhibitors |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
CA2851268A1 (en) * | 2011-10-06 | 2013-04-11 | Infersystems Corp. | Automated allocation of media via network |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
EP2647627A1 (en) | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
EP2666465A1 (en) | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
EP2668941A1 (en) | 2012-05-31 | 2013-12-04 | Almirall, S.A. | Novel dosage form and formulation of abediterol |
EP2858982A4 (en) | 2012-06-12 | 2015-11-11 | Abbvie Inc | PYRIDINONE AND PYRIDAZINONE DERIVATIVES |
WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
CA2892928A1 (en) | 2012-12-17 | 2014-06-26 | Almirall, S.A. | New use of aclidinium |
BR112015013628A2 (pt) | 2012-12-18 | 2017-07-11 | Almirall Sa | derivados de carbamato de ciclo-hexila e quinuclidinila tendo atividades agonista adrenérgica de beta2 e antagonista muscarínica de m3 |
TW201446767A (zh) | 2013-02-15 | 2014-12-16 | Almirall Sa | 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物 |
TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β2腎上腺素受體促效劑二者之活性的2-胺基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽 |
TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有maba化合物和皮質類固醇之組合 |
TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β2腎上腺素促效劑及M3蕈毒拮抗劑活性之新穎雙環衍生物 |
WO2023008885A1 (ko) * | 2021-07-27 | 2023-02-02 | 보로노이바이오 주식회사 | 피롤로피리미딘 유도체 화합물 및 이의 용도 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5679696A (en) * | 1992-07-28 | 1997-10-21 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group |
DE19533975A1 (de) * | 1995-09-14 | 1997-03-20 | Merck Patent Gmbh | Arylalkyl-diazinone |
DE19540475A1 (de) * | 1995-10-20 | 1997-04-24 | Schering Ag | Chirale Methylphenyloxazolidinone |
JP2000510848A (ja) * | 1996-05-20 | 2000-08-22 | ダーウィン・ディスカバリー・リミテッド | ベンゾフランカルボキサミドおよびこれらの治療的使用 |
DE69738949D1 (de) * | 1996-05-20 | 2008-10-09 | Darwin Discovery Ltd | Chinolincarboxamide als tnf-inhibitoren und als pde-iv inhibitoren |
KR20010024268A (ko) * | 1997-11-25 | 2001-03-26 | 로즈 암스트롱 | Pde-iv의 벤젠술폰아미드 억제제 및 그들의 치료학적용도 |
AU764005B2 (en) * | 1999-02-25 | 2003-08-07 | Merck Frosst Canada & Co. | PDE IV inhibiting compounds, compositions and methods of treatment |
US6699890B2 (en) * | 2000-12-22 | 2004-03-02 | Memory Pharmaceuticals Corp. | Phosphodiesterase 4 inhibitors |
MXPA04003516A (es) * | 2001-10-16 | 2004-07-23 | Memory Pharm Corp | Derivados de 4-(4-alcoxi-3-hidroxifenil)-2-pirrolidona como inhibidores de pde-4 para el tratamiento de sindromes neurologicos. |
AR037517A1 (es) * | 2001-11-05 | 2004-11-17 | Novartis Ag | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria |
ES2195785B1 (es) * | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
US7087625B2 (en) * | 2002-11-19 | 2006-08-08 | Memory Pharmaceuticals Corporation | Phosphodiesterase 4 inhibitors |
ES2211344B1 (es) * | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
US7226930B2 (en) * | 2003-04-18 | 2007-06-05 | Memory Pharmaceutical Corporation | Phosphodiesterase 4 inhibitors |
ES2232306B1 (es) * | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2251866B1 (es) * | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
ES2320954B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorio Almirall S.A. | Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona. |
CN102026970B (zh) * | 2007-11-21 | 2013-07-31 | 解码遗传Ehf公司 | 用于治疗肺部和心血管病症的联芳基pde4抑制剂 |
-
2004
- 2004-06-21 ES ES200401512A patent/ES2251867B1/es not_active Expired - Fee Related
-
2005
- 2005-06-20 PE PE2005000702A patent/PE20060531A1/es not_active Application Discontinuation
- 2005-06-21 JP JP2007517186A patent/JP2008503531A/ja active Pending
- 2005-06-21 RU RU2007102223/04A patent/RU2386620C2/ru not_active IP Right Cessation
- 2005-06-21 AR ARP050102533A patent/AR051738A1/es not_active Application Discontinuation
- 2005-06-21 BR BRPI0511344-0A patent/BRPI0511344A/pt not_active IP Right Cessation
- 2005-06-21 CN CNA2005800193338A patent/CN1976904A/zh active Pending
- 2005-06-21 US US11/629,527 patent/US20090029996A1/en not_active Abandoned
- 2005-06-21 NZ NZ551284A patent/NZ551284A/en unknown
- 2005-06-21 KR KR1020077001315A patent/KR20070036137A/ko not_active Application Discontinuation
- 2005-06-21 TW TW094120704A patent/TW200610757A/zh unknown
- 2005-06-21 AU AU2005254704A patent/AU2005254704A1/en not_active Abandoned
- 2005-06-21 MX MXPA06014562A patent/MXPA06014562A/es not_active Application Discontinuation
- 2005-06-21 SG SG200906269-6A patent/SG155943A1/en unknown
- 2005-06-21 WO PCT/EP2005/006712 patent/WO2005123693A1/en active Application Filing
- 2005-06-21 CA CA002570196A patent/CA2570196A1/en not_active Abandoned
- 2005-06-21 UA UAA200700276A patent/UA87691C2/ru unknown
- 2005-06-21 EP EP05752744A patent/EP1781621A1/en not_active Withdrawn
-
2006
- 2006-11-13 ZA ZA200609399A patent/ZA200609399B/xx unknown
- 2006-11-30 IL IL179741A patent/IL179741A0/en unknown
- 2006-12-08 EC EC2006007057A patent/ECSP067057A/es unknown
-
2007
- 2007-01-17 NO NO20070319A patent/NO20070319L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MXPA06014562A (es) | 2007-07-24 |
AU2005254704A1 (en) | 2005-12-29 |
PE20060531A1 (es) | 2006-06-28 |
WO2005123693A1 (en) | 2005-12-29 |
ES2251867A1 (es) | 2006-05-01 |
IL179741A0 (en) | 2007-05-15 |
NO20070319L (no) | 2007-03-06 |
CN1976904A (zh) | 2007-06-06 |
ECSP067057A (es) | 2007-03-29 |
EP1781621A1 (en) | 2007-05-09 |
CA2570196A1 (en) | 2005-12-29 |
UA87691C2 (en) | 2009-08-10 |
TW200610757A (en) | 2006-04-01 |
NZ551284A (en) | 2010-07-30 |
KR20070036137A (ko) | 2007-04-02 |
RU2386620C2 (ru) | 2010-04-20 |
RU2007102223A (ru) | 2008-07-27 |
JP2008503531A (ja) | 2008-02-07 |
SG155943A1 (en) | 2009-10-29 |
ES2251867B1 (es) | 2007-06-16 |
ZA200609399B (en) | 2008-09-25 |
US20090029996A1 (en) | 2009-01-29 |
BRPI0511344A (pt) | 2007-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051738A1 (es) | Derivados de piridazin-3(2h)-ona, composicin farmaceutica, y uso del compuesto para fabricar medicamentos | |
AR042665A1 (es) | Derivados de piridazin -3 (2 h) - ona | |
AR046445A1 (es) | Derivados de piridazin-3(2h)-ona | |
AR049402A1 (es) | Derivados de piridazin-3-(2h)-ona | |
AR040076A1 (es) | Derivados de piridazin-3(2h)-ona | |
AR059895A1 (es) | Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos | |
AR058403A1 (es) | PIRIMIDINILOXI Y PIRIDINILOXI UREAS SUSTITUíDAS COMO INHIBIDORES DE PROTEíNA QUINASAS, COMPOSICIONES FARMACÉUTICAS QUE LAS CONTIENEN Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA ACTIVIDAD BASAL DE B-RAF. | |
AR049276A1 (es) | Compuestos carboxamidos opiodes y composiciones farmaceuticas que los contienen | |
CO5700824A2 (es) | Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen | |
AR048289A1 (es) | Eteres de anillos imidazo sulfona sustituidos. | |
AR061057A1 (es) | Derivados de pirazolo(3,4-d)pirimidina utiles para desordenes respiratorios | |
TW200628452A (en) | Substituted 2-anilinopyrimidines as cell-cycle-kinase or receptor-tyrosine-kinase inhibitors, their production and use as pharmaceutical agents | |
AR059064A1 (es) | Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. | |
MX2010000658A (es) | Derivados de pirimidina 934. | |
AR057770A1 (es) | Inhibidores de la p38-map-quinasa y composicion farmaceutica | |
AR082888A1 (es) | Compuestos de piridina para la inhibicion de nampt | |
AR058719A1 (es) | Derivados de isoxazol-4-il-oxadiazol | |
CO5650247A2 (es) | Compuestos de indazol 3,5 disustituidos, composiciones farmaceuticas y metodos para intervenir en o inhibir la proliferacion celular | |
CY1107539T1 (el) | Παραγωγα κουιναζολινης | |
PE20080068A1 (es) | Compuestos derivados de pirimidina como inhibidores de la quinasa aurora | |
AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
BRPI0519288A2 (pt) | compostos heterocÍclicos como antagonistas de ccr2b | |
AR049712A1 (es) | DERIVADOS DE PIRIMIDINA COMO INHIBIDORES DE PI3K; MÉTODOS PARA SU PREPARACIoN; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO CON EFECTO ANTI-PROLIFERATIVO. | |
AR056861A1 (es) | Compuestos triciclicos fusionados como inhibidores de la necrosis tumoral. composiciones farmaceuticas y procesos de obtencion | |
CY1115643T1 (el) | Διεγερτης νευρογενεσης ή θεραπευτικος παραγων νευροπαθειας που περιλαμβανει παραγωγα αλκυλ αιθερα ή αλας αυτου |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |